


SUPPLEMENTARY FIGURES

Application of Systems Biology-Based *In Silico* Tools to Optimize Treatment Strategy Identification in Still's Disease


AUTHORS: Cristina Segú-Vergés^a, Mireia Coma^a, Christoph Kessel^b, Serge Smeets^c, Dirk Foell^b, Anna Aldea^d

AFFILIATIONS: ^aAnaxomics Biotech, Barcelona, Catalonia, Spain ^bDepartment of Pediatric Rheumatology & Immunology, University Children's Hospital, Münster, Germany ^cNovartis, Amsterdam, Netherlands ^dNovartis, Barcelona, Catalonia, Spain

Supplementary figures



Supplementary Figure S1. Schematic representation of predicted canakinumab mechanism of action over Still's disease innate immune system deregulation. The number on each link indicates to the number of the corresponding entry on Table S9, to retrieve the sources of information found in the scientific literature supporting the predicted mechanisms. Figure created to represent TPMS mechanism of action predictions using Graphviz software (<https://graphviz.gitlab.io/>).



Supplementary Figure S2. Schematic representation of predicted tocilizumab mechanism of action over Still's disease innate immune system deregulation. The number on each link indicates to the number of the corresponding entry on Table S10, to retrieve the sources of information found in the scientific literature supporting the predicted mechanisms. Figure created to represent TPMS mechanism of action predictions using Graphviz software (<https://graphviz.gitlab.io/>).